Skip to main content

Table 4 Multivariate Analyses of Survival in the Second Study Population (N = 322)

From: Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients

Variable DDFS DSS
HR 95% CI P HR 95% CI P
Age       
 > 50 yr. vs. ≤50 yr 0.56 0.29–1.07 0.08 0.34 0.13–0.92 0.033
ER status       
 Negative vs. Positive 1.01 0.49–2.06 0.99 0.58 0.19–1.75 0.33
PR status       
 Negative vs. Positive 0.82 0.39–1.72 0.60 0.86 0.30–2.50 0.79
HER2 status       
 Positive vs. Negative 1.72 0.80–3.73 0.17 4.23 1.60–11.46 0.004
Tumor size       
 > 2 cm vs. ≤2 cm 0.76 0.40–1.42 0.39 1.01 0.41–2.50 0.98
Lymph node status       
 Positive vs. Negative 2.68 1.43–5.03 0.002 3.68 1.39–9.75 0.009
Adjuvant chemotherapy       
 C vs. no therapy 1.71 0.38–7.79 0.49 1.46 0.29–7.29 0.64
 E vs. no therapy 2.53 0.44–14.62 0.30 1.67 0.20–13.69 0.63
 C + E vs.no therapy 2.11 0.47–9.47 0.33 0.92 0.17–5.01 0.63
RECQL protein expression       
 Low vs. High 2.12 1.16–3.88 0.015 2.09 0.85–5.13 0.06
  1. Abbreviations: RFS, recurrence-free survival; DRFS, distant recurrence-free survival; DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2;C,chemotherapy; E, endocrinotherapy; C + E, chemotherapy and endocrinotherapy